Molecular Partners’ Quarterly Management Statement for the period ending March 31, 2016: Phase II strategy for MP0250 laid-out, strategy about immuno-oncology pipeline disclosed, business and financial outlook 2016 fully confirmed
Monthly Archives: April 2016
At today’s AGM of Molecular Partners, the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected Jeffrey H. Buchalter as new member of the Board.
Molecular Partners announces successful completion of placement of shares.
Molecular Partners upsized the share placement transaction to a maximum aggregate sales price of approximately CHF 30,000,000.
Molecular Partners announced the launch of a selldown of shares by employees, certain consultants, and members of the board of directors of the company via an accelerated bookbuilding.